Click here for slides on this topic


ADA

Abbreviation for American Diabetes Association
The following content matched the glossary term: ADA

NDEI.org Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist

Top

In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

NDEI.org Expert Commentary Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor Sitagliptin

Top

Vivian Fonseca provides expert insights on results of the TECOS cardiovascular safety study of the DPP-4 inhibitor, sitagliptin

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

American Diabetes Association (ADA) Nutrition Guidelines for Adults With Diabetes

Top

Diabetes management guidelines for nutrition from the American Diabetes Association (ADA)

ADA/Endocrine Society

Top

 Guidelines for managing hypoglycemia in diabetes from the American Diabetes Association (ADA)/Endocrine Society

NDEI.org Press Release Interactive Case Study on ADA/EASD Diabetes Treatment Guidelines

Top

NDEI.org Interactive Case Study Explores ADA/EASD Recommendations for Individualized Treatment in Type 2 Diabetes November 15, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), announced today the launch of an interactive case study exploring the concept of individualized treatment for patients with uncontrolled type 2 diabetes.

NDEI.org Expert Commentary on ADA AGS Diabetes Treatment in Older Adults Report Silvio Inzucchi

Top

Expert commentary on American Diabetes Association (AD)/American Geriatrics Society (AGS) diabetes treatment in older adults report Silvio Inzucchi, MD.

American Diabetes Association (ADA)/American Geriatrics Society (AGS) Guidelines 2012

Top

Diabetes management guidelines for older adults from the American Diabetes Association (ADA)/American Geriatrics Society (AGS) 

Interactive Case Study: Individualized Treatment of Uncontrolled Type 2 Diabetes and CVD History

Top

The Importance of Individualizing Treatment: 58-Year-Old Man With Uncontrolled Type 2 Diabetes and Cardiovascular Disease History.

NDEI Education Council Member Silvio E. Inzucchi, MD, presents his clinical perspectives in this interactive case study based on the recent American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) Position Statement on Management of Hyperglycemia in Type 2 Diabetes.

 

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: ADA Slides Found: 240
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Inadequate Achievement of ADA Goals Among US Adults With Diabetes
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Compelling Indications for Hypertension Drug Classes
Recommended Treatment of Hypertension in Diabetes
ADA/AHA/ACC: Recommendations for Use of Aspirin for Primary Prevention of CV Events in People With Diabetes
STAMPEDE: Design
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
DPP and DPPOS: Timeline
DPP: A Look Back
DPPOS Bridge: Year 4
DPPOS Maintenance: Years 5-10
Long-Term Use of Metformin in DPPOS
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Medication Adherence
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Weight Loss
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Waist Circumference
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Achievement of ≥5% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Achievement of ≥10% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Effect of Adherence on Body Weight, Waist Circumference
Long-Term Use of Metformin in DPPOS: Results Including DPPOS Open-Label Treatment—Metformin Adherence
Long-Term Use of Metformin in DPPOS: Results During DPP—Safety & Tolerability
TODAY Study: Design
TODAY Study: Eligibility Criteria and Run-in Period
TODAY Study: Baseline Characteristics
TODAY Study: Primary Outcome—Loss of Glycemic Control
TINSAL-T2D Trial: Design
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
TINSAL-T2D Trial: Baseline Characteristics
TINSAL-T2D Trial: Primary Outcome—Change in A1C
TINSAL-T2D Trial: Change in Fasting Glucose Concentration
Long-Term Use of Metformin in DPPOS: Results During DPP—Average Hemoglobin, Hematocrit Levels Over Time
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
DPPOS Substudy: Effect of Regression from Prediabetes to NGR on Diabetes Risk
DPPOS Substudy: NGR Status and Risk Reduction
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
ORIGIN: Design
EUREXA Trial: Change in Body Weight
EUREXA Trial: Hypoglycemia and Adverse Events
EUREXA Trial: Attainment of A1C <7.0% and ≤6.5%
EUREXA Trial: Primary Outcome—Time to Treatment Failure
EUREXA Trial: Design and Enrollment Profile
EUREXA Trial: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Individualizing Treatment (1 of 2)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Individualizing Treatment (2 of 2)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Glycemia, BP, and Dyslipidemia
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (1 of 3)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (3 of 3)
ADA/Endocrine Society: Definition of Hypoglycemia in Diabetes
ADA/Endocrine Society: Classification of Hypoglycemia in Diabetes
ADA/Endocrine Society: Impact of Hypoglycemia on Glycemic Targets
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (1 of 2)
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (2 of 2)
ADA/Endocrine Society: Hypoglycemia & the Elderly
ADA/Endocrine Society: Minimizing Hypoglycemia Risks in the Elderly
ADA/Endocrine Society: Impact of Hypoglycemia on Hospitalized Patients
ADA/Endocrine Society: Hypoglycemia and Quality of Life
ADA Nutrition Guidelines: Nutrition Therapy
ADA Nutrition Guidelines: Energy Balance
ADA Nutrition Guidelines: Macronutrients
ADA Nutrition Guidelines: Eating Patterns
ADA Nutrition Guidelines: Carbohydrates
ADA Nutrition Guidelines: Quality of Carbohydrates
ADA Nutrition Guidelines: Sucrose, Fructose, Caloric Sweeteners
ADA Nutrition Guidelines: Protein
ADA Nutrition Guidelines: Fats
ADA Nutrition Guidelines: Dietary Omega-3 Fatty Acids
ADA Nutrition Guidelines: Micronutrients, Herbal Supplements
ADA Nutrition Guidelines: Alcohol
ADA Nutrition Guidelines: Priorities for Nutrition Management for All Patients
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
ADA Nutrition Guidelines: Priorities for Nutrition Management for Type 1 Diabetes and Insulin-Requiring Type 2 Diabetes
ADA Nutrition Guidelines: Summary
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
ADA Nutrition Guidelines: Sodium
LEAD 6: Percent at A1C Targets at 26 Weeks
Type 1 Diabetes Incidence & Prevalence Slide PPT | NDEI
Type 1 Diabetes Classification & Diagnosis
ADA Type 1 Diabetes Guidelines Diagnosis Clues Slide | NDEI
ADA Type 1 Diabetes Guidelines Diagnostic Criteria | NDEI
Transitional Care ADA Type 1 Diabetes Guidelines | NDEI PPT
Concomitant Autoimmunity
ADA Type 1 Diabetes Guidelines Children and Adolescent Treatment | NDEI
Type 1 Diabetes Diagnosis Follow-Up ADA Guidelines | NDEI PPT
ADA Type 1 Diabetes Guidelines DSME | NDEI Diabetes Slides
ADA Type 1 Diabetes Guidelines Nutrition Therapy | NDEI Slides
ADA Type 1 Diabetes Guidelines Physical Activity | NDEI Diabetes Slides
A1C Targets for Nonpregnant Individuals
Glycemic Goals for Adults With Type 1 Diabetes
Glucose Monitoring SMBG CGM ADA Type 1 Diabetes Guidelines | NDEI
A1C Testing ADA Type 1 Diabetes Guidelines | NDEI PPT
Insulin Therapy ADA Type 1 Diabetes Guidelines | NDEI Slides
Beta-Cell Replacement ADA Type 1 Diabetes Guidelines | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
Diabetic Ketoacidosis Management ADA Type 1 Diabetes Guidelines | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
A1C Targets Pregnancy ADA Type 1 Diabetes Guidelines | NDEI Slides
Pregnancy Recommendations ADA Type 1 Diabetes Guidelines | NDEI
Inpatient Outpatient Management ADA Type 1 Diabetes Guidelines | NDEI
Child Care Recommendations ADA Type 1 Diabetes Guidelines | NDEI
Psychosocial Issues ADA Type 1 Diabetes Guidelines | NDEI PPT
Inpatient Glycemia Targets ADA Type 1 Diabetes Guidelines | NDEI PPT
ADA EASD Hyperglycemia Management in Type 2 Diabetes PPT | NDEI
ADA EASD Type 2 Diabetes Treatment Hyperglycemia PPT | NDEI
Hyperglycemia Management Type 2 Diabetes ADA EASD PPT | NDEI
ADA EASD Pharmacologic Treatment Diabetes Hyperglycemia | NDEI
Type 2 Diabetes Treatment Options Hyperglycemia ADA EASD | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
ADA EASD Position Statement Insulin Use in Type 2 Diabetes | NDEI
ADA EASD Position Statement Individualized Glycemic Targets PPT | NDEI
AHA ADA Guidelines Diabetes CVD PPT | NDEI
AHA ADA Diabetes Diagnosis Criteria Guidelines PPT | NDEI
Lifestyle Management for CVD Prevention in Diabetes AHA ADA | NDEI
Lifestyle for Weight Loss in Diabetes AHA ADA Guidelines | NDEI
Pharmacologic Therapy for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Bariatric Metabolic Surgery for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Individualized Diabetes Therapy for CVD Prevention in Type 2 Diabetes AHA ADA | NDEI
A1C Targets AHA ADA Guidelines Type 2 Diabetes CVD Prevention | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Aspirin Therapy Type 2 Diabetes CVD Prevention PPT | NDEI
Cognitive Dysrunction in Type 2 Diabetes ADA Guidelines | NDEI PPT
Treating HIV in Patients With Diabetes | NDEI PPT
Criteria for Type 2 Diabetes Diagnosis ADA Guidelines 2016 | NDEI PPT
Screening for Type 2 Diabetes & Prediabetes in Asymptomatic Individuals
Prediabetes Increases Type 2 Diabetes Risk ADA Guidelines | NDEI PPT
Type 1 Diabetes Screening ADA Guidelines 2016 | NDEI PPT
Gestational Diabetes Mellitus (GDM) Diagnosis ADA Guidelines | NDEI PPT
Diabetes Self-Management Education DSME ADA Guidelines | NDEI
Medical Nutrition Therapy in Diabetes 2016 ADA Guidelines | NDEI PPT
Physical Activity Recommendations 2016 ADA Diabetes Guidelines | NDEI
Physical Activity in Patietns With Hypoglycemia ADA Diabetes Guidelines | NDEI
Physical Activity in Patients With Diabetes Complications ADA Guidelines | NDEI
Smoking Cessation ADA Diabetes Guidelines 2016 | NDEI PPT
Psychosocial Assessment and Care in Type 2 Diabetes ADA Guidelines | NDEI
Vaccines in Patients With Type 2 Diabetes ADA Guidelines | NDEI PPT
Type 2 Diabetes Prevention ADA Guidelines 2016 | NDEI PPT
Self-Monitoring of Blood Glucose (SMBG) in Diabetes ADA Guidelines | NDEI
Continuous Glucose Monitoring (CGM) Insulin Type 2 Diabetes ADA Guidelines | NDEI
Frequency of A1C Testing for Diabetes Diagnosis ADA Guidelines | NDEI
Glycemic Targets for Adults With Diabetes A1C ADA Guidelines | NDEI
Individualized Glycemic Targets in Diabetes ADA Guidelines 2016 | NDEI
Managing Hypoglycemia in Diabetes ADA Guidelines 2016 | NDEI PPT
Type 1 Diabetes Treatment Options ADA Guidelines 2016 | NDEI PPT
Pharmacologic Therapy for Type 2 Diabetes ADA Guidelines | NDEI PPT
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ADA Obesity Management Guidelines in Patients With Type 2 Diabetes | NDEI
Treatment for Overweight & Obesity in Type 2 Diabetes ADA Guidelines | NDEI
Obesity Treatment Options Type 2 Diabetes ADA Guidelines | NDEI PPT
Bariatric Surgery in Type 2 Diabetes ADA Guidelines | NDEI PPT
Hypertension Treatment Options in Diabetes ADA Guidelines | NDEI PPT
Lifestyle Changes for Hypertension in Diabetes ADA Guidelines | NDEI PPT
Lipid Management Recommendations ADA Diabetes Guidelines | NDEI
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Statins & Diabetes Risk ADA Guidelines 2016 | NDEI PPT
Antiplatelet Therapy Recommendations ADA Guidelines | NDEI PPT
CHD Screening & Treatment ADA Diabetes Guidelines | NDEI PPT
Cognitive Impairment & Diabetes ADA Guidelines Slide | NDEI
Hearing Impairment Is A Diabetes Comorbidity ADA Guidelines | NDEI
Low Testosterone Is A Comorbidity of Diabetes ADA Guidelines | NDEI
Fractures Are A Diabetes Comorbidity ADA Guidelines | NDEI
Cancer Is A Diabetes Comorbidity ADA Guidelines | NDEI PPT
Sleep Apnea Is A Diabetes Comorbidity ADA Guidelines | NDEI
Fatty Liver Disease Is A Diabetes Comorbidity ADA Guidelines | NDEI
Diabetes Comorbities ADA Guidelines | NDEI PPT
Glycemic Targets in Pregnancy ADA Guidelines 2016 | NDEI PPT
Diagnosing Gestational Diabetes Mellitus GDM ADA Guidelines | NDEI PPT
Type 2 Diabetes and Prediabetes Screening for Children ADA Guidelines | NDEI
Retinopathy Screening Recommendations ADA Guidelines | NDEI PPT
ADA Guidelines for Retinopathy Treatment 2016 | NDEI PPT
Neuropathy Management ADA Diabetes Guidelines 2016 | NDEI PPT
Foot Care in Patients With Diabetes ADA Guidelines | NDEI PPT
Diabetes Care for Older Adults ADA Guidelines 2016 | NDEI PPT
ADA Diabetes Guidelines Pharmacologic Therapy for Older Adults | NDEI
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI
Screening for Autoimmunities in Children With Type 1 Diabetes ADA | NDEI
2016 ADA Guidelines for Treating Hypertension in Children With Type 1 Diabetes | NDEI
ADA Guidelines for Treating Dyslipidemia in Children With Type 1 Diabetes | NDEI
ADA Guidelines Treating Microvascular Complications in Children With Type 1 Diabetes | NDEI
Pregestational Diabetes Recommendations ADA Guidelines | NDEI PPT
Management of Pregestational Diabetes ADA Guidelines | NDEI PPT
ADA Guidelines for Gestational Diabetes (GDM) 2016 | NDEI PPT
Postpartum Follow-Up for Women With Gestational Diabetes ADA Guidelines | NDEI
Managing Hypertension During Pregnancy ADA Guidelines | NDEI PPT
ADA Diabetes Care Guidelines for Hospitalized Patients | NDEI PPT
Glycemic Targets for Critically Ill Patients ADA Guidelines | NDEI PPT
ADA Glycemic Targets for Non-Critically Ill Patients With Diabetes | NDEI
Perioperative Care of Critically Ill Patients With Diabetes ADA Guidelines | NDEI
Cystic Fibrosis-Related Diabetes ADA Guidelines | NDEI PPT
Monogenic Diabetes Syndromes Diagnosis in Children ADA Guidelines | NDEI
Diabetic Kidney Disease Screening & Treatment ADA Guidelines | NDEI PPT
Vaccines in Patients With Type 2 Diabetes ADA Guidelines | NDEI PPT
Managing Diabetic Kidney Disease ADA Guidelines 2016 | NDEI PPT
Blood Pressure Treatment Targets in Diabetes ADA Guidelines | NDEI PPT
Lifestyle Changes for Obesity Management ADA Guidelines | NDEI PPT
Correlation of A1C With Average Glucose ADA Guidelines | NDEI PPT
Type 2 Diabetes & Prediabetes Screening ADA Guidelines | NDEI PPT